MOUNTAIN VIEW, Calif., Sept. 6, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following investor conferences in September:
Stifel Nicolaus Healthcare Conference
Thursday, September 8, at 2:05 p.m. ET in Boston
UBS Global Life Sciences Conference
Wednesday, September 21, at 9:30 a.m. ET in New York
A live webcast of each event will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay also will be available within 24 hours for seven days following the presentation.
About MAP Pharmaceuticals MAP Pharmaceuticals is an emerging biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. The U.S. Food and Drug Administration has accepted for filing the New Drug Application for LEVADEX for the potential acute treatment of migraine in adults. MAP Pharmaceuticals has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and Canada. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.CONTACTS: Nicole Foderaro
MAP Pharmaceuticals, Inc.(415) 946-1058
|SOURCE MAP Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved